July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Proteomic analysis of the aqueous humor: Complement activation is the major pathway in the Aqueous humor in eyes with complicated pseudophakic bullous keratopathy
Author Affiliations & Notes
  • Takefumi Yamaguchi
    Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Koji Ueda
    Project for Personalized Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan
  • Kazunari Higa
    Cornea Center Eye Bank, Tokyo Dental College Ichikawa General Hospital, Chiba, CHIBA, Japan
  • Yoshiyuki Satake
    Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan
  • Kazuo Tsubota
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Jun Shimazaki
    Ophthalmology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Takefumi Yamaguchi, None; Koji Ueda, None; Kazunari Higa, None; Yoshiyuki Satake, None; Kazuo Tsubota, None; Jun Shimazaki, None
  • Footnotes
    Support  the Grant-in-Aid for Scientific Research 15K10906 from the Ministry of Education, Culture, Sports, Science and Technology
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2905. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takefumi Yamaguchi, Koji Ueda, Kazunari Higa, Yoshiyuki Satake, Kazuo Tsubota, Jun Shimazaki; Proteomic analysis of the aqueous humor: Complement activation is the major pathway in the Aqueous humor in eyes with complicated pseudophakic bullous keratopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2905.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The long-term prognosis of corneal transplantation is poor in eyes with complicated pseudophakic bullous keratopathy (PBK), especially eyes with a history of multiple intraocular surgeries. We recently demonstrated that higher levels of specific cytokines in the aqueous humor (AqH) are associated with the rapid reduction of corneal endothelial cell loss after corneal transplantation. However, its exact mechanism is still poorly understood. We comprehensively evaluated AqH protein levels using proteomic analysis in patients with PBK and Fuchs endothelial corneal dystrophy (FECD).

Methods : We collected 100-200 μl AqH from cataract patients without any ocular comorbidities (5 eyes) and bullous keratopathy (5 eyes with PBK and 5 eyes with FECD) at the beginning of cataract surgery or endothelial keratoplasty. Proteomic analysis was conducted using Orbitrap Fusion Lumos. Gene ontology (GO) analysis was applied to the proteins which elevated only in PBK eyes, compared to cataract eyes and FECD eyes with P values less than P<0.001.

Results : The levels of 1162 proteins in the AqH were successfully quantified. Compared to cataract eyes, 69 proteins elevated only in PBK eyes, 35 proteins elevated only in FECD eyes and 33 proteins both in PBK and FECD eyes (P<0.001). Out of 30 elevated proteins only in PBK eyes (P<0.0001), 16 proteins were those related to complement pathways. Some molecules which modulate or inhibit complement systems were significantly downregulated in eyes with PBK. GO analysis showed that complement activation is the major pathway in PBK.

Conclusions : Among extensive alterations in AqH protein levels in eyes with bullous keratopathy, complement activation was identified as one of the major pathways in PBK eyes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×